Co-Diagnostics, Inc. Enters Into Lease for New, Upgraded Laboratory Facility
Laboratory will meet CGMP Requirements of
Mr. Egan continued, “This is another important milestone in the
Biocontainment precautions are required for the safe handling of
potentially dangerous biological agents in a laboratory environment.
Biological Safety Levels (“BSL”) are determined by the
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
This news release does not constitute an offer to sell or a solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Andrew Benson, 801-438-1036
Co-Diagnostics Investor Relations
Joe Diaz, 602-889-9700